Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (9451)	11/10/2003 4:59:32 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Speaking of other ways to raise HDL, this release from MATK is from today. (I have a smallish long position). The evidence for including omega-3 in your diet (most cheaply from fish oil rather than from MATK's expensive source) is compelling in my view: Press Release Source: Martek Biosciences Corporation New Study Indicates Martek's Omega-3 DHA Reduces Heart Disease Risk Factors Monday November 10, 4:45 pm ET Data Show Increased Levels of 'Good' Cholesterol, Decreased Levels Of Triglycerides and a Beneficial Shift in 'Bad' Cholesterol ORLANDO, Fla., Nov. 10 /PRNewswire-FirstCall/ -- Researchers presented results today at the American Heart Association's Scientific Sessions suggesting that 1,000 mg of DHA omega-3 fatty acid daily can favorably impact lipids and reduce cardiovascular disease risk factors in healthy adults. The study was designed to investigate the cardiovascular benefits associated with docosahexaenoic acid (DHA) and used Neuromins® DHA, manufactured by Martek Biosciences (Nasdaq: MATK - News), which comes from a natural vegetarian source and is free of contaminants that may be found in fish. ADVERTISEMENT [] A researcher from the University of Maryland enrolled 96 healthy adults with normal cardiovascular profiles in the study, randomly placed into four treatment groups. Three groups took a daily dose of 200 mg, 600 mg or 1,000 mg of DHA (Neuromins®) and the fourth group took a placebo. Patients' lipid levels were measured at the outset of the trial and again at two and four weeks of supplementation. Patients receiving DHA experienced a five percent dose-dependent increase in HDL cholesterol (known as "good" cholesterol), with maximum effect occurring with 600 mg per day. Additionally, DHA supplementation resulted in a dose-dependent decrease in patients' triglyceride levels, with a maximum 13 percent reduction occurring with 1,000 mg per day. According to the American Heart Association, high levels of HDL cholesterol reduce a patient's risk of heart attack, while patients with high levels of triglycerides are at risk for developing cardiovascular disease. According to the study, DHA supplementation also had a beneficial impact on patients' LDL cholesterol (known as "bad" cholesterol). While DHA supplementation at 600 and 1000 mg resulted in an overall five-to-eight percent increase in LDL cholesterol, this rise was largely attributed to a 28 percent increase in large, buoyant LDL particles, which pose little to no cardiovascular risk to patients. At the same time, there was no increase in small, medium or total LDL particles, which are associated with low levels of HDL cholesterol, high levels of triglycerides and increased risk of cardiovascular disease. "This study suggests that one gram of DHA per day may lower triglycerides and raise HDL cholesterol by increasing the large protective HDL particles," stated lead investigator, Harry Oken, M.D., Clinical Associate Professor of Medicine at the University of Maryland. "This study corroborates other research indicating that DHA may promote cardiovascular health." "The evidence continues to accumulate on DHA cardiovascular benefits," stated Henry "Pete" Linsert, Jr., Chairman and CEO of Martek. "Martek believes this study clearly indicates that DHA is the ultimate omega-3 fatty acid for patients seeking improved heart health." Additional studies demonstrating the cardioprotective nature of Martek's Neuromins® DHA will be presented at AHA's Scientific Sessions on Wednesday, Nov. 12. Neuromins® DHA contains the vegetarian, contaminant-free, Kosher, Halal omega-3 fatty acid manufactured under FDA inspected, GMP (Good Manufacturing Practice) conditions. The product is marketed nationwide as an adult nutritional supplement. For more information on DHA, visit www.DHADepot.com.

To: Biomaven who wrote (9451)	11/10/2003 6:30:15 PM
From: robert miller	Respond to of 52153

Peter, Adrian Adams addressed the issue of the Pfizer drug on the CC after the 2nd quarter. It was his opinion that if things went right for Pfizer it would be 4-5 years before it could come to market. bob